Big Pharma is becoming adept at identifying new uses for old drugs. Companies are re-examining established therapies – conducting refocused clinical research within the relatively new context of genome mapping. With increasing clarity, we are able to see how drugs impact cell behavior and operations, and this ability is yielding promising results in the treatment of various forms of cancer. Recent research out of Boston has revealed that a 50 year old antipsychotic medication called perphenazine may be called back into active duty – this time to battle acute lymphoblastic leukemia (ALL), a particularly aggressive form of cancer. The research.. READ MORE »
